APEH as a target for treating hyperuricemia and its related kidney injury and application thereof
By targeting APEH and increasing its expression or activity, the shortcomings of treatment strategies for hyperuricemia and kidney damage have been addressed, achieving more effective uric acid clearance and renal protection.
CN122376746APending Publication Date: 2026-07-14ZHEJIANG CHINESE MEDICAL UNIVERSITY
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ZHEJIANG CHINESE MEDICAL UNIVERSITY
- Filing Date
- 2026-04-16
- Publication Date
- 2026-07-14
Smart Images
Figure CN122376746A_ABST
Abstract
The application discloses APEH as a target point for treating hyperuricemia and related kidney injury and application thereof, and belongs to the technical field of biological medicine. The application aims to solve the problems of insufficient target point innovation, incomplete mechanism evidence chain, insufficient system recovery of renal tubular uric acid excretion, and limited efficacy and safety in the existing treatment technology of hyperuricemia and related kidney injury, and provides a new uric acid-lowering treatment target point and application scheme, so as to realize a more effective and more expandable treatment strategy. The application proposes that acylpeptide hydrolase (APEH) is used as a treatment target point for regulating uric acid homeostasis, and a new strategy of improving uric acid metabolism abnormality by improving APEH expression or activity is constructed, so as to form an expandable target point route and support the discovery and development of different types of APEH modulators.
Need to check novelty before this filing date? Find Prior Art